Clinical utility of intraductal carcinoma of the prostate in treatment selection for metastatic hormone‐sensitive prostate cancer

The findings highlight a high prevalence of IDC-P among patients with mHSPC and suggest that IDC-P positivity may be a reliable indicator that ARAT should be implemented as first-line treatment.